Drug Profile
MK 2118
Alternative Names: MK-2118Latest Information Update: 02 Feb 2023
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 02 Feb 2023 Phase I development is ongoing in USA (NCT03249792)
- 28 Dec 2022 Merck Sharp & Dohme completes a phase-I clinical trials in Solid tumours and Lymphoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (Intratumoural) (NCT03249792)
- 28 Dec 2022 Merck Sharp & Dohme completes a phase-I development in Solid-tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Intratumoural, Injection)